101 related articles for article (PubMed ID: 21586629)
1. Pharmacodynamic evaluation of the target efficacy of SB939, an oral HDAC inhibitor with selectivity for tumor tissue.
Novotny-Diermayr V; Sausgruber N; Loh YK; Pasha MK; Jayaraman R; Hentze H; Yong WP; Goh BC; Toh HC; Ethirajulu K; Zhu J; Wood JM
Mol Cancer Ther; 2011 Jul; 10(7):1207-17. PubMed ID: 21586629
[TBL] [Abstract][Full Text] [Related]
2. Phase I and pharmacodynamic study of an orally administered novel inhibitor of histone deacetylases, SB939, in patients with refractory solid malignancies.
Yong WP; Goh BC; Soo RA; Toh HC; Ethirajulu K; Wood J; Novotny-Diermayr V; Lee SC; Yeo WL; Chan D; Lim D; Seah E; Lim R; Zhu J
Ann Oncol; 2011 Nov; 22(11):2516-2522. PubMed ID: 21385886
[TBL] [Abstract][Full Text] [Related]
3. Pracinostat (SB939), a histone deacetylase inhibitor, suppresses breast cancer metastasis and growth by inactivating the IL-6/STAT3 signalling pathways.
Chen J; Li N; Liu B; Ling J; Yang W; Pang X; Li T
Life Sci; 2020 May; 248():117469. PubMed ID: 32109485
[TBL] [Abstract][Full Text] [Related]
4. Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours.
Razak AR; Hotte SJ; Siu LL; Chen EX; Hirte HW; Powers J; Walsh W; Stayner LA; Laughlin A; Novotny-Diermayr V; Zhu J; Eisenhauer EA
Br J Cancer; 2011 Mar; 104(5):756-62. PubMed ID: 21285985
[TBL] [Abstract][Full Text] [Related]
5. SB939, a novel potent and orally active histone deacetylase inhibitor with high tumor exposure and efficacy in mouse models of colorectal cancer.
Novotny-Diermayr V; Sangthongpitag K; Hu CY; Wu X; Sausgruber N; Yeo P; Greicius G; Pettersson S; Liang AL; Loh YK; Bonday Z; Goh KC; Hentze H; Hart S; Wang H; Ethirajulu K; Wood JM
Mol Cancer Ther; 2010 Mar; 9(3):642-52. PubMed ID: 20197387
[TBL] [Abstract][Full Text] [Related]
6. Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile.
Wang H; Yu N; Chen D; Lee KC; Lye PL; Chang JW; Deng W; Ng MC; Lu T; Khoo ML; Poulsen A; Sangthongpitag K; Wu X; Hu C; Goh KC; Wang X; Fang L; Goh KL; Khng HH; Goh SK; Yeo P; Liu X; Bonday Z; Wood JM; Dymock BW; Kantharaj E; Sun ET
J Med Chem; 2011 Jul; 54(13):4694-720. PubMed ID: 21634430
[TBL] [Abstract][Full Text] [Related]
7. Preclinical metabolism and disposition of SB939 (Pracinostat), an orally active histone deacetylase inhibitor, and prediction of human pharmacokinetics.
Jayaraman R; Pilla Reddy V; Pasha MK; Wang H; Sangthongpitag K; Yeo P; Hu CY; Wu X; Xin L; Goh E; New LS; Ethirajulu K
Drug Metab Dispos; 2011 Dec; 39(12):2219-32. PubMed ID: 21873472
[TBL] [Abstract][Full Text] [Related]
8. Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity.
Ning ZQ; Li ZB; Newman MJ; Shan S; Wang XH; Pan DS; Zhang J; Dong M; Du X; Lu XP
Cancer Chemother Pharmacol; 2012 Apr; 69(4):901-9. PubMed ID: 22080169
[TBL] [Abstract][Full Text] [Related]
9. Antimalarial activity of the anticancer histone deacetylase inhibitor SB939.
Sumanadasa SD; Goodman CD; Lucke AJ; Skinner-Adams T; Sahama I; Haque A; Do TA; McFadden GI; Fairlie DP; Andrews KT
Antimicrob Agents Chemother; 2012 Jul; 56(7):3849-56. PubMed ID: 22508312
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of class I histone deacetylases by romidepsin potently induces Epstein-Barr virus lytic cycle and mediates enhanced cell death with ganciclovir.
Hui KF; Cheung AK; Choi CK; Yeung PL; Middeldorp JM; Lung ML; Tsao SW; Chiang AK
Int J Cancer; 2016 Jan; 138(1):125-36. PubMed ID: 26205347
[TBL] [Abstract][Full Text] [Related]
11. Discovery of PAT-1102, a novel, potent and orally active histone deacetylase inhibitor with antitumor activity in cancer mouse models.
Hiriyan J; Shivarudraiah P; Gavara G; Annamalai P; Natesan S; Sambasivam G; Sukumaran SK
Anticancer Res; 2015 Jan; 35(1):229-37. PubMed ID: 25550555
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the antitumor efficacy, pharmacokinetics, and pharmacodynamics of the histone deacetylase inhibitor depsipeptide in childhood cancer models in vivo.
Graham C; Tucker C; Creech J; Favours E; Billups CA; Liu T; Fouladi M; Freeman BB; Stewart CF; Houghton PJ
Clin Cancer Res; 2006 Jan; 12(1):223-34. PubMed ID: 16397046
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic activity of the histone deacetylase inhibitor SB939 on renal fibrosis.
Kang SW; Lee SM; Kim JY; Kim SY; Kim YH; Kim TH; Kang MS; Jang WH; Seo SK
Int Immunopharmacol; 2017 Jan; 42():25-31. PubMed ID: 27855304
[TBL] [Abstract][Full Text] [Related]
14. YM753, a novel histone deacetylase inhibitor, exhibits antitumor activity with selective, sustained accumulation of acetylated histones in tumors in the WiDr xenograft model.
Shindoh N; Mori M; Terada Y; Oda K; Amino N; Kita A; Taniguchi M; Sohda KY; Nagai K; Sowa Y; Masuoka Y; Orita M; Sasamata M; Matsushime H; Furuichi K; Sakai T
Int J Oncol; 2008 Mar; 32(3):545-55. PubMed ID: 18292931
[TBL] [Abstract][Full Text] [Related]
15. Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling.
Qian C; Lai CJ; Bao R; Wang DG; Wang J; Xu GX; Atoyan R; Qu H; Yin L; Samson M; Zifcak B; Ma AW; DellaRocca S; Borek M; Zhai HX; Cai X; Voi M
Clin Cancer Res; 2012 Aug; 18(15):4104-13. PubMed ID: 22693356
[TBL] [Abstract][Full Text] [Related]
16. Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
Yang Z; Wang T; Wang F; Niu T; Liu Z; Chen X; Long C; Tang M; Cao D; Wang X; Xiang W; Yi Y; Ma L; You J; Chen L
J Med Chem; 2016 Feb; 59(4):1455-70. PubMed ID: 26443078
[TBL] [Abstract][Full Text] [Related]
17. Benzimidazole and imidazole inhibitors of histone deacetylases: Synthesis and biological activity.
Bressi JC; de Jong R; Wu Y; Jennings AJ; Brown JW; O'Connell S; Tari LW; Skene RJ; Vu P; Navre M; Cao X; Gangloff AR
Bioorg Med Chem Lett; 2010 May; 20(10):3138-41. PubMed ID: 20392637
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of Histone Deacetylase Inhibitor Sensitivity in Combination with Cyclin-Dependent Kinase Inhibition for the Treatment of Oral Squamous Cell Carcinoma.
Zhao B; Huang Z; Qin Z; Li Y; Wang T; Wang L; Zhou W; Yu C; Wang X; Yang S; Fan Y; Xiang R
Cell Physiol Biochem; 2019; 53(1):141-156. PubMed ID: 31237760
[TBL] [Abstract][Full Text] [Related]
19. Preclinical Development of the Class-I-Selective Histone Deacetylase Inhibitor OKI-179 for the Treatment of Solid Tumors.
Diamond JR; Pitts TM; Ungermannova D; Nasveschuk CG; Zhang G; Phillips AJ; Bagby SM; Pafford J; Yacob BW; Newton TP; Tentler JJ; Gittleman B; Hartman SJ; DeMattei JA; Winkler JD; Wendt MK; Schiemann WP; Eckhardt SG; Liu X; Piscopio AD
Mol Cancer Ther; 2022 Mar; 21(3):397-406. PubMed ID: 34965958
[TBL] [Abstract][Full Text] [Related]
20. Intracellular vorinostat accumulation and its relationship to histone deacetylase activity in soft tissue sarcoma patients.
Burhenne J; Liu L; Heilig CE; Meid AD; Leisen M; Schmitt T; Kasper B; Haefeli WE; Mikus G; Egerer G
Cancer Chemother Pharmacol; 2017 Aug; 80(2):433-439. PubMed ID: 28612091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
